American interest is the quest for money savings. However, in the health sector, especially where China is involved, this search can prove to be fatal. In tandem with Chinese investment in the pharmaceutical industry, the current progress towards generic medicine poses a risk to our nation’s health, economy, and national security.
Just conjecture. It’s not speculation. In 2008, at least 81 Americans were killed by a tingled blood thinner produced in China. Victims are not known to persons of all ages and fitness, including boys. After the tragedy, the Chinese carried out an adequate inquiry.
The thinner form of blood is no exception and needs to be treated as well. The French authorities have found some years after the original tragedy, several samples that might have been tampered with and that claim to be tested for the mask.
Evidence of cancer components in high blood pressure, cardiovascular disease, and hypertension drugs have been identified in recent years. Who is responsible? External firms, China in particular.
China has taken over the market by providing lower production costs which concentrate on generics. But the cost is inexpensive and our wellbeing and maybe our nation’s security can be the price.
There are three sections to the question. Firstly, low prices foster corner cuts that life and death should never allow.
Nonetheless, Chinese international inspections are seen as a concern and sometimes even risk the safety of the country. In the United States, this is an integral part of the safety procedures for the possibility of surprise tests.
Sadly, Americans aren’t safe from generic drugs made in other parts of the world or even those with overseas ingredients.
Our critical dependency puts us at a major strategic disadvantage in addition to the risk to health. China is a well-known intellectual property rights violator. In the field of medicine, this is particularly dangerous, as it threatens American creativity, which is so vital for new life-saving therapies.